Thar Pharmaceuticals is focused on the identification and development of new forms of widely prescribed drugs that solve clinical opportunities such as improved bioavailability, efficacy, absorption, safety or toxicity.  It is estimated that the clinical performance of seventy percent of currently marketed drugs can be improved. 

Thar focuses on two areas:

We apply our pharmaceutical co-crystal technology to identify and develop new, proprietary forms of widely prescribed drugs which we will commercialize through pharmaceutical partners;

We provide our co-crystal technology, our supercritical-fluid based particle design technology and our supercritical-fluid based polymorph screening technology as a service to partners and customers.